Site Search
Professionals 189 results
Capabilities 58 results
Practice Area
Today’s dynamic commercial real estate market calls for attorneys who bring a broad platform of skills and experience to the table. Our real estate practice offers institutional knowledge across an extensive array of real estate transactions.
Practice Area
Our REIT attorneys are experienced in the planning and implementation of a variety of organizational and real estate ownership structures used for REIT formations and transactions. We understand the complex requirements of asset ownership and character of income that must be met to qualify for pass-through tax treatment under the Internal Revenue Code. Our team has extensive experience with IPOs, private placement of debt, securitization of debt, public/private preferred and common equity offerings, PIPE transactions, recapitalizations, trust preferred securities, asset purchase and dispositions, §1031 exchanges, and mergers and acquisitions. Our experience in capital raising (via public and private securities offerings), securitization, and structured finance transactions is just as deep.
Practice Area
Bankruptcy Litigation & Investigations
Large corporate bankruptcies and companies in financial distress often spawn a complex web of claims by lenders, trustees, debtors, creditors, creditors’ committees, investors, shareholders, and other constituents. Attorneys in Winston & Strawn’s complex commercial litigation group and special situations and restructuring group serve as trusted advisors and resolute advocates to protect clients’ business interests and assets in multifaceted Chapter 11 cases and bankruptcy-related disputes.
Experience 72 results
Experience
|March 18, 2026
Winston & Strawn LLP Advises Maxim Group LLC on $100 Million IPO of BHAV Acquisition Corp
Winston & Strawn LLP represented the underwriter, Maxim Group LLC, in connection with the $100 million initial public offering of BHAV Acquisition Corp. The offering consisted of 10,000,000 units priced at $10.00 per unit, with each unit comprising one Class A ordinary share and one right. Each right entitles the holder to receive one-fourth (1/4) of one Class A ordinary share upon the consummation of the Company’s initial business combination.
Experience
|February 22, 2026
Winston & Strawn LLP Paris advised the Compagnie Européenne de Garantie et Caution (CEGC, BPCE Group) financial creditors on the adoption of Réalités’ recovery plan by the Nantes Commercial Court.
Experience
|July 24, 2025
Winston & Strawn LLP represented Linkhome Holdings Inc., a leading AI-powered U.S. real estate platform, in connection with its upsized $6 million initial public offering. The offering consisted of 1,500,000 shares of common stock priced at $4.00 per share, and the shares are expected to begin trading on the Nasdaq Capital Market under the ticker “LHAI” on July 24, 2025.
Insights & News 634 results
In the Media
|April 7, 2026
|2 Min Read
Winston & Strawn Co-Executive Chair Jeffrey Kessler was featured in Global Competition Review discussing his role representing a coalition of 35 states in the ongoing antitrust litigation against Live Nation.
Non-Fungible Insights: Blockchain Decrypted
|March 26, 2026
|6 Min Read
FCA Handbook Application for Regulated Cryptoasset Activities – Key Takeaways from CP26/4
The close of 2025 highlighted the continuing momentum for the digital asset industry, with regulatory developments accelerating rather than slowing.
Client Alert
|March 19, 2026
|7 Min Read
Law Firms: The Next Frontier for Private Equity in Professional Services?
Law firms are one of the last major professional services segments without meaningful private equity (PE) penetration. The core investment attributes are familiar:
Other Results 29 results
Law Glossary
What Statutes and Regulations Govern the Approval and Marketing of Biosimilars?
Congress passed the Biologics Price Competition and Innovation Act of 2009 (BPCIA) in 2010 an amendment of the Public Health Services Act. The BPCIA is codified at 42 U.S.C. § 262.
Law Glossary
What Exclusivity Periods Are Associated with Biosimilars?
An applicant may not submit an aBLA until four years after the reference product is licensed by the FDA. (See BPCIA § 351(k).) Further, any biosimilar licenses “may not be made effective” until 12 years after the reference product was licensed. (See BPCIA § 351(l).)
Law Glossary
What Is the Difference Between a Biosimilar and a Generic Drug?
A biosimilar is a biologic product that—as the name implies—is similar to its reference product. Because of a biologic’s complexity, it is not possible to synthesize identical biosimilars that are identical copies of their associated reference products.